Some observational studies suggest a lower risk of new depression diagnoses among GLP-1 users compared to those taking other diabetes or weight-loss medications
Rseau canadien dinfo-traitements sida (CATIE)
Jastreboff AM, Kaplan LM, Fras JP, et al
As your body adjusts to these changes, temporary side effects can occur, particularly during the early stages of treatment or after dose increases
The primary actions of GLP-1 include stimulating insulin secretion from pancreatic beta cells in response to elevated blood glucose (importantly, this insulin release is glucose-dependent, reducing hypoglycaemia risk), suppressing glucagon release (which prevents the liver from producing excess glucose), and slowing gastric emptying
These are the ones well focus on here